Injective Cut Its Emissions. Now It Needs Revenue To Catch Up

The governance upgrade known as IIP-617, passed by INJ token holders in January, sought to tighten INJ issuance and double the network's deflation rate. In market language, it was a supply-side intervention. Less new INJ paid out to validators – the nodes that secure the network and process transactions – and delegators should mean less structural sell pressure. Combined with Injective's buyback-and-burn mechanism, the goal was to push INJ closer to a deflationary monetary model – one where usage and ecosystem revenue remove more tokens than staking rewards create.

Six months later, the evidence is mixed but useful. The Supply Squeeze is clearly visible in the data. Injective's token-incentive burden has fallen sharply, even after adjusting for price. Earnings have improved because the network is paying out far less in staking rewards. But the harder part of the thesis remains unproven. Fees and ecosystem revenue are still small relative to the security budget. Injective has fixed a large part of the supply problem. It has not yet shown that demand-side revenue is strong enough to make net deflation a durable reality.

All data in this piece are sourced from Token Terminal as of mid-June 2026.

Supply side has changed

INJ sits at the centre of Injective's economic system. It is used for staking, governance and transaction fees. Validators and delegators stake INJ to secure the network and receive staking rewards. Those rewards are the cost of security, but they are also a new token supply. That is the trade-off every proof-of-stake network has to manage: pay enough to secure the chain, but not so much that token holders are diluted faster than the ecosystem can generate value.

Injective's tokenomics involve two opposing forces. On one side, new INJ is issued to reward validators and delegators. On the other, INJ can be removed from supply through burn mechanisms funded by ecosystem activity. The older burn-auction model routed application revenue into INJ burns. The newer community buyback mechanism lets participants commit INJ in exchange for a share of ecosystem revenue, with the committed INJ permanently burned.

In theory, this creates a link between network usage and token scarcity. More activity should mean more ecosystem revenue, larger buybacks and more INJ removed from supply. But that only works if burns are large enough to offset issuance. A network can call itself deflationary, but if it mints more tokens through staking rewards than it burns through revenue-funded mechanisms, supply still grows.

IIP-617 was important because it attacked the issuance side directly. Instead of relying solely on larger burns, Injective reduced the amount of INJ paid out as staking rewards. That makes the deflationary equation easier to satisfy. If fewer tokens are minted each week, the burn mechanism does not need to work as hard to push net supply lower.

(Source: Token Terminal)

The data support that interpretation. In the four weeks before the January upgrade window, Injective's weekly expenses averaged roughly $730,000. In the four weeks after, they averaged about $253,000 – a decline of 65%. Since expenses are reported in dollars, part of that fall can be explained by INJ's lower price. But even after adjusting for price, the implied native-token incentive burden fell by about 50%.

That is the clearest evidence that the supply squeeze had a real fundamental impact. Before IIP-617, Injective was paying out roughly 130,000–145,000 INJ per week in staking incentives. In Q1, that fell to about 86,000 INJ. In Q2, it declined further to roughly 70,000 INJ per week.

Annualized, the implied incentive run-rate moved from more than 7mn INJ before the upgrade to closer to 3.6mn INJ in Q2. That is not cosmetic. It is a meaningful reduction in dilution pressure.

Savings, not earnings

The bottom-line impact is clear. Injective's latest weekly expenses were about $276,000, down 84% year over year and 64% from the start of 2026. Weekly earnings remain negative, but the loss has narrowed sharply. The latest weekly earnings figure was about minus $81,000, compared with roughly minus $1.55mn a year earlier. On a quarterly basis, weekly earnings improved from around minus $1.35mn in Q2 2025 to about minus $246,000 in Q2 2026.

For token holders, that is good news. The protocol is spending fewer tokens to maintain security, which means less structural issuance and less potential sell pressure from staking rewards.

But it is not the same as saying Injective has become a strong fee-generating business. The improvement is mostly coming from lower incentives, not from a surge in revenue. That distinction matters.

Fees remain thin. Latest weekly fees were about $9,500, down 75% year over year and more than 95% below the late-2023 peak in the dataset. Q2 was better than Q1, with average weekly fees rising from about $11,900 to $18,400, but the absolute level remains small relative to the security budget.

The direction has improved, but the level remains weak. In Q2, fees covered only about 5.7% of protocol expenses, leaving Injective still heavily dependent on token incentives to fund validator rewards. At the same time, implied staking incentives were still running at roughly 70,000 INJ per week, or about 280,000 INJ per month. That sets the practical hurdle for the deflationary thesis: monthly burns need to exceed that level, unless issuance falls further. IIP-617 made that target more achievable by cutting the issuance burden but did not by itself prove that INJ has entered a sustained deflationary regime.

Usage is healthier than monetization

The broader network data are not bearish. In several places, they are reasonably strong. Network usage has held up better than revenue. As of mid-June, weekly active users stood at roughly 102,000, up 51% year over year, although 14% below the start of 2026. Daily active addresses – unique wallets interacting with the network – were more resilient, at about 86,600, up 73% year over year and only 3% below the dataset high. On those measures, Injective's user base has not deteriorated in the same way as its fee base.

(Source: Token Terminal)

Transaction data are more mixed. Total weekly transactions were about 8.9mn, down 74% year-over-year and 81% below the July 2025 peak. On its own, that looks poor. But ecosystem contract transactions – interactions with smart contracts deployed by applications on the network – give a more constructive signal. The latest contract transactions were about 904,000, roughly flat year over year, up 17% from the start of 2026, and only 14% below the dataset peak. It suggests Injective may have shed a large amount of low-value or repetitive transaction activity, while application-level contract interaction has remained more resilient. In other words, the chain appears to have less raw throughput but still meaningful app usage.

For a finance-focused chain, that is not irrelevant. Contract-level interaction is closer to the core economic activity Injective wants to capture. If users are interacting with applications rather than simply generating empty or low-value transactions, the network may be healthier than total transaction counts imply.

The problem is that usage has not translated into meaningful fee capture. Active addresses are close to highs, but fees are not. Contract interactions are resilient, but revenue remains small. That gap is the main weakness in the fundamental story.

Some of this may be structural. Injective is designed to be cheap to use. Low fees can help attract traders and applications, especially in markets where latency and cost matter. But for token holders, cheap blockspace is only valuable if it drives enough volume or ecosystem revenue to fund meaningful burns. Otherwise, high activity becomes a weak value-accrual signal. That is why raw user growth should not be overstated. The relevant question is not only whether people are using Injective. It is whether that usage produces economic value large enough to matter for INJ.

Market has not fully bought the story

Market data suggest investors are paying attention but not yet repricing INJ as a proven deflationary asset. INJ is trading around $5.55, down 49% year-over-year and still 88% below its March 2024 high. The token is modestly positive year to date, but the scale of the drawdown shows how far the market has de-rated the asset since the last cycle of enthusiasm.

Trading activity has improved from depressed levels. Spot volume was up 141% year over year and almost 5.8 times higher than at the start of 2026. Futures volume was up 167% year to date, while perpetual futures open interest – the total value of outstanding derivatives contracts – was up 92%. Those are signs of renewed attention and positioning.

But they do not yet point to a broad speculative reset. Spot volume, futures volume and open interest remain far below their 2024 peaks. Recent seven-day averages are also below 30-day averages, suggesting momentum cooled into mid-June.

(Source: Token Terminal)

That is probably the correct market response. IIP-617 makes INJ a cleaner supply story. It does not, by itself, make INJ a fully proven value-accrual story. Investors appear to be treating the supply squeeze as an improvement in tokenomics rather than proof of a new economic regime.

In crypto, emission cuts can trigger powerful narratives because they are easy to understand. Fewer tokens entering circulation should be good for price, all else equal. But that logic only holds if fees are growing, application revenue is scaling, and market demand is durable. Injective has improved one side of the equation. The other side still has to be earned.

Cleaner tokenomics, incomplete proof

Injective's January supply squeeze was a meaningful upgrade. It reduced the protocol's staking-incentive burden by roughly half in native-token terms and materially improved the earnings profile. That lowers dilution pressure and makes the burn mechanism more relevant.

But lower issuance is not the same as sustained deflation. At the Q2 run-rate, Injective was still paying roughly 70,000 INJ per week in staking rewards, or about 280,000 INJ per month. The threshold is therefore straightforward: burns need to exceed that level, unless staking rewards fall further. IIP-617 lowered the hurdle materially, but the case for sustained net deflation still depends on the burn mechanism scaling alongside ecosystem revenue.

That leaves INJ in a better position than it was before IIP-617, but not an unambiguous one. Tokenomics has become more investor-friendly. User activity remains relatively healthy, and contract-level interaction has been resilient. Yet fees remain too small to settle the debate, covering only 5.7% of protocol expenses in Q2. The supply side has been tightened. The revenue side has not yet caught up.